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Abstract
Prednisolone used in the induction phase of the treatment of acute lymphoblastic leukemia (ALL) may suppress
hypothalamic–pituitary–adrenal axis and require hydrocortisone substitution. In this retrospective analysis, we
reviewed altogether 371 ACTH stimulation tests of 352 children after a uniform NOPHO (Nordic Society of
Pediatric Hematology and Oncology) ALL induction. Both low- and standard-dose ACTH tests were used. Full
recovery of adrenal function was defined by both normal basal and stimulated cortisol levels. Sixty-two percent of
patients were detected with normal adrenal function in median of 15 days after tapering of prednisolone. Both low
basal and stimulated cortisol levels were detected in 13% of patients. The median time to normal adrenal function was
31 days (95% CI 28–34), 24 days (95% CI 18–30), and 12 days (95% CI 10–14) for those with basal cortisol <107,
107–183, and >183 nmol/L at first ACTH testing, respectively. Patients with fluconazole prophylaxis had higher
median baseline cortisol levels compared to patients without prophylaxis (207 nmol/L, range 21–839 nmol/L vs.
153 nmol/L, range 22–832 nmol/L, P = 0.003).
Conclusion: These data can be used to reduce unnecessary substitution or testing, but also to guarantee hydrocortisone
substitution for those at risk.
What is Known:
•These data can be used to reduce unnecessary hydrocortisone substitution or ACTH testing.
•Our data helps to guarantee hydrocortisone substitution for those at risk of adrenal insufficiency.
What is New:
•Full recovery of adrenal function after ALL induction is detected in 62% of patients already at 15 days after tapering of prednisolone.
•Both basal and stimulated cortisol testing are required for detection of full adrenal recovery.
•Recovery time of adrenal function is extended over 3–4 weeks after tapering of prednisolone in patients with low basal cortisol levels
(<107 nmol/L) at first testing.
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Abbreviations
ALL Acute lymphoblastic leukemia
NOPHO Nordic Society of Pediatric
Hematology and Oncology
Introduction
The treatment results of childhood acute lymphoblastic leuke-
mia (ALL) have improved over the last five decades and
shown an event-free survival (EFS) of over 90% in patients
with favorable clinical and biological risk factors features [8,
13, 15]. This progress is due to intensive multi-agent chemo-
therapy, better understanding of the biological features of
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leukemia [5], and not least to rapid evaluation of response to
early induction therapy [2, 8, 16].
Corticosteroids have been a fundamental part of induction
therapy since the earliest successes in ALL therapy [9]. Both
prednisolone and dexamethasone have been used in the con-
temporary protocols [8, 15, 16]. Nevertheless, the optimal
dosing of corticosteroids, to optimize the ratio of efficacy to
adverse effects, some of which are lifelong, has not been
established [4].
High-dose glucocorticoid treatment is known to cause sup-
pression of the hypothalamic–pituitary–adrenal (HPA) axis,
and this may lead to hypoplasia and even atrophy of the adre-
nal cortex [1]. Thus, the body’s own glucocorticoid produc-
tion may be suppressed after a long-lasting or high-dose glu-
cocorticoid treatment causing a life-threatening risk if ade-
quate substitution is not administered.
Adrenal insufficiency is a known consequence of a high-
dose glucocorticoid treatment during induction therapy of
ALL treatment in children. Earlier studies have shown a vary-
ing incidence and duration of adrenal insufficiency as well as a
controversy regarding the need of hydrocortisone substitution
[10]. The ideal time point of testing of the adrenal function
during intensive ALL therapy, interpretation of the results and
length of hydrocortisone substitution, need further evaluation.
The purpose of this study was to find out the prevalence and
duration of adrenal insufficiency in pediatric patients after
ALL induction therapy with prednisolone.
Patients and methods
For this retrospective study, we identified all patients (N =
352) treated for acute lymphoblastic leukemia (ALL) in the
Children’s Hospital, Helsinki University Hospital from 1992
to 2014. During this time, patients have been treated on three
consecutive Nordic protocols for ALL: NOPHO-ALL 92
(January 1992 to October 2001), NOPHO-ALL 2000
(January 2002 to June 2008), and NOPHO-ALL 2008
(July 2008 to February 2016). ALL 92 and ALL 2000 proto-
cols included patients from the age of 1 year up to 14.9 years,
and ALL 2008 protocol patients from the age of 1 year up to
17.9 years.
For this study, only patients who had received
prednisolone-based induction were included (N = 316). This
included patients treated with NOPHO-ALL 92 (n = 139) and
ALL 2000 (n = 97) protocols [12], but from NOPHO-ALL
2008 protocol only those with B-cell precursor (BCP) leuke-
mia and white blood cell (WBC) count less than 100 × 109/L
at diagnosis [15] (N = 80). Altogether, 46 patients were ex-
cluded either due to induction failure, missing information, or
protocol violation (Fig. 1).
The basic demographic information, leukemia-related pa-
rameters, detailed information about the dose and duration of
the prednisolone treatment and of the hydrocortisone substi-
tution after induction, information about other medication
used during the induction, as well as detailed information
about the timing, mode, and results of the ACTH-
stimulation tests were collected from the patient records and
from the local leukemia registry. Unfortunately, the cytogenet-
ic and minimal residual disease testing was not performed
uniformly during the three protocol eras, and, thus, could not
be used in the analyses.
The study was approved by the Research Ethics Committee
of the Helsinki University Hospital.
Induction therapy
The induction therapy consisted of prednisolone (60 mg/
m2/day) for days 1–36 (ALL 92, ALL 2000) or for days
1–29 (ALL 2008), doxorubicin (40 mg/m2) two (ALL
2000, ALL 2008) or three (ALL 92) times, vincristine
(2 mg/m2, capped at 2–2.5 mg) six times (ALL 92 and
ALL 2000) or five times (ALL 2008), and intrathecal
methotrexate (days 1, 8, 15, and 29). L-Asparginase
(E. coli) was given intramuscularly at 30,000 E/m2/day
Fig. 1 Consort diagram of study patients for analysis of adrenal recovery
after prednisolone induction for acute lymphoblastic leukemia. Patients
have been treated on NOPHO (Nordic Society of Pediatric Hematology
and Oncology) ALL 92 (N = 139), ALL 2000 (97), and ALL 2008 (80)
protocols
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on days 36–46 (ALL 92) or at 6500 IU/m2/day on days
37, 40, 44, and 47 (ALL 2000), or as PEG-asparginase at
1000 U/m2 on day 30 (ALL-2008), all given before the
first adrenal function tests. Prednisolone was tapered
down in 9 days, and hydrocortisone substitution was
started the day after (Supplementary Table 1).
Adrenal function testing
After tapering of prednisolone, hydrocortisone (HC) was giv-
en with a recommended dose of 10 mg/m2/day until ACTH
stimulation test indicated normal HPA function or next treat-
ment phase with corticosteroids was due. This was week 14 in
ALL 2008 and ALL 92 and week 28 in ALL 2000 from start
of induction.
During the early part of the study period, standard-
dose ACTH-stimulation test was performed. In the
s t anda rd -dose s t imu la t i on t e s t , t e t r acosac t i de
(Synacthen®) was given intravenously at 0.25 mg/
1.73 m2 in the morning between 7:00 and 9:00.
Samples for serum cortisol measurement were drawn be-
fore and at 60 and 120 min after the administration of
tetracosactide. Due to the change in the institutional pol-
icy in 2012, the test was changed to a low-dose test
using tetracosactide at 1 μg/1.73 m2, and serum cortisol
level was measured before and at 30 min after the ad-
ministration of tetracosactide.
The detection limit of the serum cortisol test (HUSLAB,
Helsinki, Finland, immunochemiluminometric assay) was at
20 nmol/L and non-stimulated basal morning values over
69 nmol/L were defined normal. Stimulated cortisol values
above 500 nmol/L and 300 nmol/L were considered normal
in the standard- and low-dose tests, respectively.
Statistical analyses
Due to differences in the stratification between the protocols,
the National Cancer Institute (NCI) risk classification was
used for grouping the patients resulting into three groups:
NCI standard risk group (N = 164) (B-cell immunophenotype,
age <10 years and WBC <50 × 109/L), NCI high risk group
(N = 85) (B-cell immunophenotype, age >10 years or WBC
>50 × 109/L), and T-ALL group (N = 21) [14]. Bilineage and
biphenotype ALL patients (N = 21) were classified into the B
cell group.
Mann–Whitney U test, Kruskal–Wallis test, and
Spearman’s rank correlation tests were used as indicated in
the text. These tests were chosen because the material was
not normally distributed. P values less than 0.05 were consid-
ered significant.
Kaplan–Meier and Cox regression analyses were used to
create a prognostic model for the recovery of the adrenal func-
tion. Normal adrenal function was set as the clinical endpoint.
The follow-up time was calculated from the start of HC sub-
stitution. Multivariate analyses included only ACTH tests
done within 60 days after initiation of HC substitution (the
shortest interval to the next protocol phase with corticoste-
roids). Accordingly, results from 263 ACTH tests were
included.
The study population was initially divided into four groups
according to the baseline cortisol value (<107.0 nmol/L,
107 . 01–183 . 0 nmo l /L , 183 . 01–273 . 0 nmo l /L ,
<273.0 nmol/L). The purpose of this grouping instead of in-
dividual analysis was to have equal-sized groups and more
power for the analyses.
The significance of factors included into the univari-
ate analyses were age, gender, risk group, duration until
first adrenal testing, use of fluconazole in induction,
hydrocortisone dose, cumulative hydrocortisone dose,
baseline value of the first adrenal testing, and baseline
grouping. A multivariate model for the recovery of the
HPA axis was created based on the univariate analysis.
A time-dependent Cox regression model was created
because the data did not fulfill the proportional hazard
assumption required by the standard multivariate Cox
regression.
Results
The final study population included 270 patients with a medi-
an age of 4.6 years (range 1.1–16.2). Detailed demographic
data of the study population are presented in Table 1. The
majority of the patients (95%, 257/270) had no other chronic
disease. One patient suffered from diabetes, five were on asth-
ma medication, and seven patients had Down syndrome.
Fluconazole prophylaxis was used during induction phase
for 158 patients (59%). Only one patient was treated in ICU
during the observation period, thus it had no major effect on
our results.
Prednisolone induction therapy lasted for 35 days
(median, range 21–60). The exact length of prednisolone
therapy varied a little because of clinical reasons, e.g.,
infections causing minor delays in chemotherapy. Twelve
patients had prednisolone therapy over 40 days, all of
Table 1 Demographic data on study patients (N = 270)
Age at diagnosis in years: mean (range) 4.7 (1.1–16.8)
Gender: girls/boys 131/139
WBC: median (range) 11.8 × 109 (0.5–986.1)
Immunophenotype: BCP-ALL/T cell/MPAL 228/21/21
Risk group: T cell/NCI-SR/NCI-HR 21/164/85
WBC white blood cell count, NCI-SR NCI standard risk, NCI-HR NCI
high risk, MPAL mixed phenotype acute leukemia
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whom were treated according to ALL 1992 and 2000
protocols (protocol prednisolone duration 36 days). The
exact induction phase prednisolone therapy duration was
shorter than in the protocol in 83/207 (ALL 92 and ALL
2000) and 36/63 (ALL 2008) patients, and longer in 78/
207 (ALL 92 and ALL 2000) and 14/63 (ALL 2008)
patients.
Data on 371 ACTH-stimulation tests of these 270 patients
were collected. Low-dose and standard-dose ACTH tests were
performed to 23 patients (8.5%) and to 247 patients (91.5%),
respectively. The first adrenal function test was performed at
10 days (median, range 0–78) from the end of prednisolone
course.
The median morning basal cortisol was 184 nmol/L (range,
below detection limit–839) in the first test. Altogether, 36
patients (13%) had values lower than the reference range, 10
(3.7% of total study population) of whom had undetectable
cortisol levels (Fig. 2). Prepubertal patients (1–9.9 years)
showed significantly lower morning basal cortisol levels than
older children (10–16.8 years) (P = 0.008) (Supplementary
Fig. 1).
The median peak result in the first low- and standard-dose
ACTH test was 381 nmol/L (range 51–600) and 569 nmol/L
(range 29–1853), respectively. In total, 103 patients (38.1%)
had an insufficient response in the first test (Table 2), with no
difference between low-dose and standard-dose tests
(Supplementary Fig. 2). A normal adrenal response was de-
tected at 15 days (median, range 0–78) days after stopping
prednisolone. Thirty-four (13.6%) patients had both abnormal
basal and stimulated levels. Both a normal basal and a normal
stimulated cortisol level were detected in 167 (61.9%) patients
(Table 2).
As expected, patients with insufficient adrenal response in
the first test had their test significantly earlier than patients
with sufficient adrenal response (median 8 days, range 0–
57 days vs. 12 days, range 0–78 days; P = 0.025).
Boys tested with the standard-dose ACTH test showed
lower stimulated cortisol values than girls in the first test (me-
dian 532 nmol/L, range 73–1162 nmol/L vs. 593 nmol/L,
range 29–1853 nmol/L; P = 0.017). This gender difference
was not detected by the low-dose ACTH test (P = 0.558).
Patients who received antifungal prophylaxis (fluconazole,
a CYP3A4 inhibitor) had significantly higher baseline cortisol
levels in the first test than patients without prophylaxis (me-
dian 207 nmol/L, range 21–839 nmol/L, two under detection
limit vs. median 153 nmol/L, range 22–832 nmol/L, eight
under detection limit; P = 0.003).
Leukemia-related parameters (immunophenotype, WBC,
NCI-risk category) or underlying other diseases did not have
an association with the adrenal function results.
Hydrocortisone substitution
Several patients had multiple ACTH tests before HPA recov-
ery (59 had two, 21 had three or more). Three patients had
their test immediately after stopping prednisolone and never
received HC substitution.
A sufficient adrenal response was detected in 206/270 pa-
tients (76.3%) before the next treatment phase with corticoste-
roids. A total of 64 patients did not reach sufficient adrenal
response before the next treatment phase.
The median hydrocortisone substitution dose was 7.8 mg/
m2 (range 2.3–34.4). Hydrocortisone substitution lasted for
22 days (median, range 1–120). Interestingly, hydrocortisone
Fig. 2 Adrenal function recovery with time (in days). The figure illustrates the variability in time of testing. It also shows the increasing percentage of
patients with normal basal cortisol secretion
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substitution was discontinued in 53 patients (19.6%) despite
insufficient adrenal response in the stimulation test.
Factors contributing to full recovery of HPA axis
We defined the full recovery of HPA axis by the patient having
both normal baseline and normal stimulated cortisol levels. In
particular, we wanted to study the value of basal cortisol level
in predicting the duration of HC substitution until the full
recovery of adrenal function. To study this, the patients were
first divided into four equal-sized groups based on morning
basal cortisol values. The two groups with the highest basal
cortisol levels showed no difference in the time needed to
reach normal adrenal function and were merged into one
group including 50% of the patients. Thus, final analysis in-
cluded three groups: group 1 (n = 66) with morning cortisol
<107.00 nmol/L, group 2 (n = 66) with morning cortisol
107.01–183.00 nmol/L, and group 3 (n = 131) with morning
cortisol >183.01 nmol/L. These groups are from now on
called baseline cortisol value groups. There was no statistical-
ly significant difference in time point of the first adrenal test
performed (p = 0.079) between these groups.
The median time to normal adrenal function in group 1 was
31 days (95% CI 28–34), 24 days in group 2 (95% CI 18–30)
and 12 days in group 3 (95% CI 10–14). The probability for
recovery changed between days 20 and 30 for group 3, but for
the other two groups the recovery was more linear with time
(Supplementary Fig. 3). Patients in group 1 (basal cortisol
level below 107 nmol/L) have little chance of adrenal function
recovery before the next ALL treatment phase with cortico-
steroids (Supplementary Fig. 3).
We built a Cox univariate regression model to study the
patient-, leukemia-, and treatment-related factors on full adre-
nal recovery: NCI-risk group, cumulative hydrocortisone
dose, duration of substitution until first adrenal testing, base-
line of the first adrenal test, and baseline groups showed sta-
tistically significant impact on recovery. Age, gender, flucon-
azole use, and HC dose were not statistically significant
factors.
Then, a multivariate Cox regression model was built with
all the variates included in the univariate Cox regression anal-
ysis. A model including age, NCI-risk classification, duration
until first adrenal test, and baseline group was statistically
significant for all variates (Supplementary Table 2). The value
of low basal cortisol was even more pronounced in predicting
abnormal adrenal function when the variation was adjusted by
age, risk classification, and duration until first adrenal testing
as contributing factors (Fig. 3).
The proportional hazard assumption was not fulfilled for
the duration until the first adrenal test or baseline grouping,
meaning that the hazard ratios for these variates are not con-
stant over time. Thus, to control this, we performed a time-
dependent Cox regression model starting after day 20
(Supplementary Fig. 3).
Patients in baseline group 2 were 10 times more likely to
recover within the observation period (60 days) than patients
in group 1, and patients in baseline group 3 were 14 times
more likely to recover than patients in group 1. The probabil-
ity for recovery decreases with age (Supplementary Table 3).
Discussion
In our study of 270 patients after prednisolone-induction ther-
apy of ALL, many of the patients (61.9%) had a normal adre-
nal function in stimulation test done 15 days (median, range
0–78) after tapering of prednisolone. Samples were drawn
with a wide distribution in time. This shortcoming, however,
reflects the clinical real world including varying condition of
the patients caused by infections etc.
Adrenal insufficiency defined either as a low baseline or a
low stimulated level was detected in 38.1% of patients after 4-
week prednisolone induction therapy. This is in line with ear-
lier studies showing that up to 20–70% [3, 7] of children with
ALL have adrenal insufficiency after the induction therapy. In
addition, Petersen et al. showed that 40% of patients suffer
from adrenal insufficiency for over 8 weeks [7]. Cochrane
review including 10 studies concluded that impaired adrenal
function is common after the induction treatment of childhood
ALL and that it usually occurs a few days after tapering of
prednisolone [10]. We showed that the earlier the adrenal
stimulation test was done, the more likely it showed insuffi-
cient response. Our data show that the recovery of the HPA
axis is detected in median of 15 days after tapering of
Table 2 Basal and stimulated
cortisol levels in first ACTH test
in 270 patients after ALL
induction with prednisolone
Low dose Standard dose Total
Low baseline, low stimulated level 2 (8.7%) 32 (13%) 34 (12.6%)
Low baseline, normal stimulated level 0 (0%) 2 (0.8%) 2 (0.7%)
Normal baseline, low stimulated level 5 (21.7%) 62 (25.1%) 67 (24.8%)
Normal baseline, normal stimulated level 16 (69.6%) 151 (61.1%) 167 (61.9%)
23 247 270
Basal cortisol levels above 69 nmol/L and stimulated values above 500 nmol/L and 300 nmol/L were considered
normal in the standard- and low-dose tests
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prednisolone. This helps in planning of the scheduling of ad-
renal testing and duration of HC substitution. In addition, we
found that morning cortisol values may work well as a screen-
ing test for adrenal insufficiency.
Several factors contributed to the recovery of adrenal func-
tion. Younger children (<10 years) showed lower morning
cortisol values, but the multivariate model indicated that older
children are at bigger risk of creating a prolonged adrenal
insufficiency. Younger children therefore seem to recover
faster. This may be explained by adrenarche after which the
relative amount of cortisol production is reduced because of
the increased production of sex steroids. No gender difference
was detected in the low-dose ACTH test. This may be due to
the small sample size (n = 23).
Patients who had received antifungal prophylaxis during
their induction therapy showed higher morning cortisol values
and shorter duration of HC substitution compared to those
without antifungals. This is at least partly explained by the
inhibition of CYP3A4 by fluconazole. CYP3A4 plays an im-
portant role in the metabolism of corticosteroids. The
Cochrane review also suggests that clinicians should pay spe-
cial attention to patients who have received fluconazole during
their induction therapy [10]. Earlier studies have shown that
fluconazole has a delaying effect on the adrenal recovery with
fluconazole doses over 10 mg/kg/day [11]. This may be due to
higher steroid concentrations. The prophylactic dosing of flu-
conazole in our unit has been below this, at 5 mg/kg/day.
The difference between low-dose and standard-dose
ATCH-stimulation tests turned out to be smaller than
expected. Standard-dose ACTH-stimulation tests are done
using supraphysiological ACTH doses which may result in
falsely high stimulated cortisol levels. The low-dose ACTH
test works as a more physiological simulation of the adrenal
function in stress situations. Standard-dose ACTH test has a
higher specificity while low-dose is more sensitive but has a
lower specificity [6]. Stimulation tests give us more extensive
information about the adrenal function than basal cortisol
measurements. We analyzed results from two different
ACTH stimulation tests. Age was included in the original
univariate analyses, but it had no statistical significance.
Twenty-two patients had adrenal function tests
misinterpreted resulting in unnecessary hydrocortisone substi-
tution and retesting. Furthermore, hydrocortisone substitution
was discontinued in 53 patients (19.6%) despite insufficient
adrenal response. These errors point out the difficulty in the
interpretation of ACTH test results in clinical setting.
Our study was retrospective, thus the data may have some
sources of bias. We had a chance to collect a considerable
number of patients and ACTH tests for our analyses. Wemade
an effort to statistically control for the bias caused by age of
the patient, timepoints for testing, hydrocortisone dose and
duration as well as leukemia-related factors.Multivariate anal-
ysis was problematic because of the proportional hazard as-
sumption not being fulfilled. At the end, the results of the
time-dependent analysis did not differ much from the tradi-
tional Cox regression, but we consider that the time-dependent
analyses make the interpretation of the results more reliable
considering the usual clinical setting.
Fig. 3 Full adrenal recovery time after prednisolone as function of basal
cortisol level. Patients were divided into three groups according to the
basal cortisol level at first ACTH test after tapering of prednisolone. Basal
cortisol groups <107, 107–183, and >183.01 nmol/L are indicated in
blue, red, and yellow, respectively
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Appropriate treatment and testing are required. Uncertainty
among clinicians leads to unnecessary testing and incorrect
HC substitution endings. The value of morning cortisol indi-
cating sufficient adrenal function varies. We chose the value
used by our fully accredited laboratory. The goal of this study
was not to set a certain level but to understand the adrenal
recovery better. A multi-professional work together with clear
instructions improve treatment and reduce error. Based on our
study, we recommend weekly morning cortisol measurements
after the induction steroid therapy. Once a sufficient level is
achieved, HC substitution can be limited to stress situations
only, and low-dose ACTH test should be performed. This test
should be repeated fortnightly until normal.
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